Pancreatic Cancer Breakthrough: Experimental pill receives FDA fast-track designation by May 5

48%

probability · 48% confidence · 14 days

Health signals report experimental pancreatic cancer pill improving survival in late-stage study. FDA fast-track designation is a logical near-term milestone given clinical momentum. Base rate for drug approval pathway events (90 days): 30%, but this is a narrower outcome (fast-track vs full approval), reducing probability. Signal specificity about late-stage success supports moderate confidence.

Brunu publishes AI-generated probability forecasts on world events, markets, and policy. Forecasts update as new signals come in and are graded correct/incorrect at close — full track record at brunu.ai/forecasts. Informational only. Not financial, legal, or medical advice.